Kinesis Pharma and Venn Life Sciences will join forces
I am pleased to announce that Kinesis Pharma (Kinesis) and Venn Life Sciences (Venn) will join forces in offering drug development services to the pharmaceutical and biotech industry as well as to investors in these areas. The companies have entered into an agreement under which Venn will acquire the entire issued share capital of Kinesis.
Kinesis provides specialised services in chemical-pharmaceutical, nonclinical, and early clinical drug development. Venn is strong in clinical trial management in later stages and resourcing solutions to pharmaceutical, biotechnology, medical device and academic organisations. The combined services of Venn and Kinesis Pharma allow us to offer a complete range of services from lead selection, drug substance/drug product development, pharmacokinetics to full clinical trial management services. Together with the extensive regulatory knowledge of our combined teams, we are looking forward to offering our national and international clients an enhanced service offering across Europe.
For more information on Venn Life Sciences, see www.vennlifesciences.com
For Kinesis clients little will change in the day-to-day running of activities. As always our teams will keep performing to the highest standards, serving our clients with an even broader expertise in conjunction with our Venn colleagues. We will remain as Kinesis Pharma, as part of the Venn Life Sciences Group: one partner, all the brains you need.
On a personal level, I will be staying on with the company and, together with my colleagues, support our clients in these exciting times in the drug development arena.
Kees Groen, Founder and CEO.